Maxim Group Has Lowered Expectations for Autonomix Medical (NASDAQ:AMIX) Stock Price

Autonomix Medical (NASDAQ:AMIX) had its price objective reduced by research analysts at Maxim Group from $5.00 to $2.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 439.08% from the company’s previous close.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $2.00.

Autonomix Medical Stock Up 1.3%

Shares of AMIX stock opened at $0.37 on Tuesday. The company’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.87. Autonomix Medical has a 52 week low of $0.34 and a 52 week high of $3.09. The stock has a market cap of $2.56 million, a P/E ratio of -0.10 and a beta of -2.58.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings data on Wednesday, February 11th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.10. On average, analysts anticipate that Autonomix Medical will post -10 EPS for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.